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Background: Cultural views of Attention-Deficit/Hyperactivity Disorder (ADHD), differing healthcare systems and
funding mechanisms, and the availability of mental health services can greatly influence the perceptions, diagnosis,
and treatment of ADHD. There is, however, lack of information about treatment practice and the treatment
decision-making process for ADHD, particularly in non-Western countries. Our study compared characteristics of
paediatric patients newly diagnosed with ADHD symptoms who did and who did not initiate treatment, and also
examined whether any differences varied by region in Central Europe and East Asia.
Methods: Data were taken from a 1-year prospective, observational study that included 1,068 paediatric patients
newly diagnosed with ADHD symptoms. Clinical severity was measured using the Clinical Global Impression-ADHD-
Severity (CGI-ADHD-S) scale and the Child Symptom Inventory-4 (CSI-4) checklist. Logistic regression was used to
explore patient characteristics associated with treatment initiation (pharmacotherapy and/or psychotherapy) at
baseline for each region.
Results: A total of 74.3% of patients initiated treatment at baseline (78.3% in Central Europe and 69.9% in East Asia).
Of these, 48.8% started with both pharmacotherapy and psychotherapy in Central Europe, and only 17.1% did so in
East Asia. The level of clinical severity was highest in the combination treatment group in Central Europe, but was
highest in the psychotherapy only group in East Asia. In East Asia, treatment initiation was associated with being
older, being male, and having a higher CGI-ADHD-S score. In Central Europe, treatment initiation was associated
with parental psychological distress, having a higher CSI-4 score, and not being involved in bullying.
Conclusions: Although factors associated with treatment initiation differed to some extent between Central Europe
and East Asia, clinical severity appeared to be one of the most important determinants of treatment initiation in
both regions. However, the choice between pharmacotherapy and psychotherapy, either alone or in combination,
varied substantially across the regions.
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Attention-Deficit/Hyperactivity Disorder (ADHD) is a
neurobehavioural condition, characterised by the core
symptoms of inattention and/or hyperactivity/impulsivity
[1]. It is among the most prevalent mental disorders in
childhood and adolescence across countries and regions
[2]. Although data on the prevalence of ADHD in non-
Western countries (e.g., Central Europe and East Asia) are
limited, the available evidence suggests that prevalence
rates in these regions are similar to those in Western
countries, ranging from 7.5% to 12% among school-aged
children and adolescents [3-7].
Treatment for ADHD typically involves both pharmaco-
therapy and psychoeducational/behavioural treatments, ei-
ther alone or in combination [8-10]. Several international
guidelines on ADHD support the use of these treatment
options, although a discrepancy exists between the U.S.
[10] and European guidelines in the treatment preferences
for first-line therapy [8,11]. For example, the U.S. guide-
lines developed by the American Academy of Paediatrics
recommend the first-line use of pharmacotherapy, prefera-
bly combined with behavioural therapies, for school-aged
children and adolescents with ADHD, but only behav-
ioural therapies for preschool-aged children [10], whereas
the European guidelines developed by the European Net-
work for Hyperkinetic Disorders and the UK guideline
developed by the National Institute for Health and Care
Excellence recommend that the use of drug treatments be
reserved only for those with severe symptoms and impair-
ments or when patients fail to respond to an initial trial of
psychological treatments [8,11]. Although European guide-
lines are, in general, more conservative about the use of
pharmacotherapy as a first-line therapy for ADHD due to
concerns over potential adverse events during treatment
with ADHD medications (albeit rare and mostly manage-
able [12]), these guidelines consider both pharmacotherapy
and psychotherapy as important treatment options for
ADHD and suggest that patient age and clinical severity are
the most important clinical factors to consider when mak-
ing treatment decisions for ADHD.
The limited available evidence on the factors associated
with treatment initiation is largely consistent with these
international guidelines [13,14]. Using data from a 2-year
observational study in Europe, Falissard et al. found that
the initiation of pharmacotherapy at the baseline visit was
associated with more severe ADHD symptoms and im-
pairments [13]; however, the study was primarily descrip-
tive and did not examine the associations with other
factors. The only study that has explicitly explored patient
characteristics associated with the initiation of ADHD
treatment was a study by Chen et al. based in the United
States [14]. While they analysed the initiation of medica-
tion among patients with a new ADHD episode using
Florida Medicaid claims data, the study was unable toassess the impact of clinical severity on treatment deci-
sion due to data constraints and also focused more on
the choice between ADHD medications and other psy-
chiatric medications in the treatment of ADHD. The
study reported that the initiation of ADHD medications
was associated with being older and being male, as well
as other patient characteristics including race (White),
rural dwelling, foster care, and the diagnosis by primary
care physicians [14].
Although patient age and clinical severity are likely to
play important roles in the treatment decision-making
process for ADHD, a recent study based on the opinions
of and feedback from international leaders in this area
confirmed the great deal of variation in ADHD diagnosis
and treatment practices across and within countries [15].
Cultural views on the disorder, differing healthcare sys-
tems and funding mechanisms, and the availability of
mental health services were assumed to greatly influence
perceptions, diagnosis, and treatment of ADHD. For ex-
ample, the study indicated that as in the United States,
Canadian health professionals tend to view “ADHD as an
impairing, often life-long disorder that requires careful as-
sessment and multimodal intervention” [15]. In addition, a
wide range of pharmacological and psychosocial interven-
tions are made accessible to the general population
through the nationalised healthcare system. Meanwhile,
ADHD is still greatly underdiagnosed and undertreated in
many parts of the world due to the high levels of stigma
attached to mental illness, lack of acceptance of ADHD as
a disorder, limited access to services, lack of training in
the treatment of ADHD among medical and mental health
professionals, and the high acceptance of herbal treat-
ments and homeopathy in some cultures. Although there
is lack of empirical evidence on treatment practices for
ADHD in non-Western countries, the role of clinical se-
verity in the treatment decision-making process may be
greater in these regions because the stigma attached to
mental illness and the preference for homeopathic and
herbal remedies are likely stronger, thereby the use of psy-
chiatric treatments/medications is likely less accepted in
these regions.
Using data from a 1-year, prospective, observational
study involving 1,068 paediatric patients newly diagnosed
with ADHD symptoms from Central Europe and East
Asia, this study compared the demographic and clinical
characteristics of those patients who did and did not initi-
ate treatment in routine clinical practice in Central Europe
and East Asia and examined whether any differences be-
tween them varied by region.
Methods
Study design and patient sample
This was a 12-month, international, prospective, non-
interventional, observational study primarily designed to
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among paediatric patients newly diagnosed with ADHD
symptoms in actual clinical practice. From October 2005
to July 2006, fifty-eight psychiatrists and paediatricians
enrolled a total of 1,068 paediatric patients from eight
countries across Central Europe and East Asia (China
[n = 301], the Czech Republic [n = 50], Hungary [n = 96],
Romania [n = 82], Slovakia [n = 55], South Korea [n =
100], Taiwan [n = 101], and Turkey [n = 283]). This study
followed the ethical standards of responsible local com-
mittees and regulations from the participating countries,
was conducted in accordance with the ethical principles
of the Declaration of Helsinki, and is consistent with
good clinical practice when applicable to a study of this
nature. Ethical Review Board (ERB) approval was ob-
tained wherever required by local law for observational
studies (see Additional file 1). The parents/guardians of
all patients provided written informed consent, and the
patients provided assent. Further details on the study de-
sign have been reported elsewhere [16-20].
Child and adolescent outpatients aged 6 to 17 years
could participate in the study if they presented within
the normal course of care with ADHD symptoms and
had not been previously diagnosed with or treated for
ADHD. The diagnosis of ADHD symptoms was made by
an investigator using standard diagnostic criteria (Diag-
nostic and Statistical Manual of Mental Disorders-4th
edition-text revision [DSM-IV-TR] [21] or International
Classification of Diseases-10 [ICD-10] [22]). That is, in
the clinical judgment of the investigator, at baseline the
participating patients were required to have hyperactive,
inattentive, or impulsive symptoms or problems associ-
ated with ADHD as described in the DSM-IV-TR or
hyperkinetic disorders, disturbance of activity and atten-
tion, or hyperkinetic conduct disorder as described in
the ICD-10. The study excluded those patients who had
severe mental retardation (i.e., those unable to attend
school due to mental disability), those who had epilepsy
or schizophrenia, or those who were participating in a
different study that included use of a treatment interven-
tion or investigational drug.
Data collection for the study occurred during visits within
the normal course of care. Baseline data were collected
from the routine outpatient visit in which patients were en-
rolled. Subsequent data collection was targeted at 1 month
after the baseline visit and then every 3 months (3, 6, 9, and
12 months) after the baseline visit. Patient demographics
and clinical history were recorded at the baseline assess-
ment. Clinical severity of ADHD symptoms were assessed
by treating physicians at each visit using the Clinical Global
Impressions-ADHD-Severity (CGI-ADHD-S) scale [23] and
Category A of the Child Symptom Inventory-4 Parent
Checklist (CSI-4) [24]. The physician-rated version, of
which CSI-4 scores were recorded by the treatingphysicians in consultation with parents, was used after
converting scores to norm-referenced standardised
CSI-4 scores using U.S.-based population norms.
Treatment cohorts
Patients could be prescribed any treatment regimen by the
treating physician. Treatment decisions were made solely
at the discretion of the physician, patient, or parent/guard-
ian and were independent of study participation. In actual
practice, patients could receive no treatment/intervention,
psychotherapy, pharmacotherapy, a combination of psy-
chotherapy and pharmacotherapy, or other treatments.
The most commonly prescribed medication at baseline
was methylphenidate (45.5% [n = 486/1,068] of the total
sample; 69.0% [n = 486/704] of patients who were pre-
scribed at least one medication). Psychotherapy included
formal sessions of psychoeducation and counselling, cogni-
tive behavioural therapy, hypnotherapy, family therapy, or
psychodynamic therapy that were conducted by a certi-
fied healthcare provider at a regular frequency for an
acceptable length of time. Other treatments included
educational interventions, speech therapy, occupational
therapy, herbal therapy/homeopathy, informal hypnosis,
psychomotor/physiotherapy, electroencephalogram bio-
feedback, diet exclusion, diet supplementation, and relax-
ation techniques. Further details on treatment patterns are
available elsewhere [16].
Patients were categorised into two groups for the
current analysis. The no treatment group included pa-
tients who received no ADHD treatments/interventions
and patients who received other treatments at baseline.
The treatment group included patients who were pre-
scribed pharmacotherapy, psychotherapy, or both at base-
line. As shown in Table 1, all three treatment groups (i.e.,
psychotherapy only, pharmacotherapy only, and both) had
higher levels of clinical severity than the two no treatment
groups (i.e., no treatments/interventions and other treat-
ments). The level of clinical severity among patients who
initiated psychotherapy only was highest in East Asia but
was similar to those who initiated pharmacotherapy with/
without psychotherapy in Central Europe.
Statistical analysis
Mean patient age and clinical severity by different types of
treatments or no treatments prescribed at baseline (i.e., no
treatments/interventions, other treatments, psychotherapy
only, pharmacotherapy only, and the combination of psy-
chotherapy and pharmacotherapy) were first examined
and compared using one-way analysis of variance. Baseline
characteristics of the patients who did and did not initiate
treatment (i.e., psychotherapy, pharmacotherapy, or both)
at baseline were then summarised and compared using t
tests (for numerical variables) and chi-square tests (for
categorical variables).
Table 1 Mean (SD) patient age and clinical severity by type of treatments prescribed at baseline
Variables No TX Other TX Psycho Pharmaco Combi P value
All
Patient age 8.60 (2.49) 7.90 (2.14) 8.66 (2.06) 9.13 (2.61) 9.24 (2.51) <0.001
CGI-ADHD 4.16 (1.01) 4.33 (0.94) 4.80 (1.12) 4.51 (0.93) 4.55 (1.01) <0.001
CSI-4 72.63 (11.02) 73.58 (10.30) 76.31 (10.08) 75.29 (10.49) 78.65 (10.43) <0.001
East Asia only
Patient age 8.60 (2.66) 7.61 (1.98) 9.05 (2.15) 9.20 (2.58) 8.95 (2.41) <0.001
CGI-ADHD-S 4.01 (0.86) 4.50 (0.95) 5.23 (0.90) 4.52 (0.93) 4.65 (0.99) <0.001
CSI-4 71.21 (10.95) 73.22 (9.38) 76.25 (9.68) 74.61 (9.08) 73.33 (9.27) 0.022
Central Europe only
Patient age 8.59 (2.32) 8.64 (2.38) 8.34 (1.95) 9.04 (2.66) 9.32 (2.54) 0.037
CGI-ADHD-S 4.30 (1.11) 3.91 (0.75) 4.46 (1.16) 4.49 (0.93) 4.53 (1.01) 0.041
CSI-4 73.99 (10.96) 74.50 (12.55) 76.35 (10.49) 76.25 (12.16) 80.14 (10.27) <0.001
Abbreviations: SD standard deviation, ADHD attention-deficit/hyperactivity disorder, CGI-ADHD-S Clinical Global Impressions-ADHD-Severity, CSI-4 Child Symptom Inventory-4
Parent Checklist, TX treatment, Psycho psychotherapy only, Pharmaco pharmacotherapy only, Combi the combination of both psychotherapy and pharmacotherapy.
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patient characteristics associated with treatment initi-
ation at baseline. The model included patient age, gen-
der, age at first symptoms, region (Central Europe or
East Asia), birth problems, family history of ADHD, and
CGI-ADHD-S score. The model also included the fol-
lowing variables, but only if they appeared to be signifi-
cant at p < 0.1 in simple logistic regressions: body mass
index (BMI) (kg/m2), having other children living at
home, mother having paid employment, father having
paid employment, emotional health problems of parents/
guardians due to their children’s behavioural problems,
having been truant in the 4 weeks before baseline, having
been involved in bullying (as a bully) in the 4 weeks before
baseline, having primary care visits for behavioural prob-
lems in the 4 weeks before baseline, having been invited to
social activities in the 4 weeks before baseline, and CSI-4
score. All analyses were repeated for each region, with the
same list of the variables included in the model for the
whole sample. The interactions between each factor and
region were also examined to check whether the behav-
iour of the factors in treatment initiation, statistically
significantly, differs by region. Each interaction model in-
cluded region, each specific factor, and their interaction
term. It should however be noted that the statistical sig-
nificance of these interaction terms could be more mean-
ingfully interpreted when the factors exhibit different
directions of associations with treatment initiation in the
regional subgroup analyses. In this case, the p-values of
the interaction terms can indicate whether the different
associations observed between regions are indeed statisti-
cally significant. Otherwise, their interpretations could be
less straightforward. For instance, their interaction terms
could appear to be non-significant when the behaviour of
the factors in treatment initiation is similar betweenregions but the characteristics of the factors themselves
still differ by region.




A total of 1,068 paediatric patients newly diagnosed with
ADHD symptoms were included in this analysis (n = 566 in
Central Europe and n = 502 in East Asia). Approximately
three-quarters of these patients (74.3%, n = 794) initiated
pharmacotherapy and/or psychotherapy at baseline (8.4%
for psychotherapy only, 40.1% for pharmacotherapy only,
and 25.8% for both) (Figure 1). The rate of treatment initi-
ation was higher in Central Europe (78.3%) than in East
Asia (69.9%) (p = 0.002). This difference was mainly attrib-
utable to a higher rate of other treatments prescribed in
East Asia (11.2% in East Asia and 3.9% in Central Europe)
(Figure 1). Another notable difference between the two re-
gions was a higher prescription rate for combined pharma-
cotherapy and psychotherapy in Central Europe (48.8%)
than in East Asia (17.1%).
Table 1 summarises mean (standard deviation [SD]) pa-
tient age and mean (SD) clinical severity for the five treat-
ment types prescribed at baseline in each region. In East
Asia, the mean level of clinical severity was highest in pa-
tients who initiated psychotherapy only (CGI-ADHD-S,
5.23 [SD 0.90]; CSI-4, 76.25 [SD 9.68]), whereas it was low-
est in a subgroup of patients who did not initiate any treat-
ments/interventions (CGI-ADHD-S, 4.01 [SD 0.86]; CSI-4,
71.21 [SD 10.95]). Mean patient age was lowest in those
with other treatments (7.61 years [SD 1.98]), followed by
those with no treatments/interventions (8.60 [SD 2.66]). In
Central Europe, the mean level of clinical severity was high-

































No treatment Other treatment Psychotherapy
Pharmacotherapy Pharmaco+Psycho
Figure 1 Type of treatments prescribed at baseline. Note that
patients were categorised into two cohorts (no treatment and treatment)
for the current analysis. The former includes patients who received no
treatment and other treatment, and the latter includes patients who
received pharmacotherapy and/or psychotherapy at baseline.
Table 2 Baseline patient characteristics by treatment
initiation at baseline




Age, mean (SD)* 8.40 (2.41) 9.12 (2.52)
Male, % 81.68 82.38
Age at first symptoms, mean (SD) 5.50 (2.43) 5.49 (2.33)
Being from East Asia
(vs. Central Europe), %*
55.11 44.21
BMI (kg/m2), mean (SD) 18.01 (3.49) 18.31 (3.64)
Birth problems, %* 19.35 29.91
Family history of ADHD, % 40.20 47.10
Having other children living at home, % 54.25 57.47
CGI-ADHD-S, mean (SD)* 4.21 (0.99) 4.56 (0.98)




Paid employment (mother), %* 78.13 69.01
Paid employment (father), % 89.45 87.32
Parental psychological distress due to
their children’s behavioural problems, %*
38.15 51.26
Being truant in the 4 weeks
before baseline, %*
4.18 8.75
Being involved in bullying (as a bully)
in the 4 weeks before baseline, %
25.58 22.68
Primary care visit for behavioural problems
in the 4 weeks before baseline, %*
7.42 14.08
Being invited to social activity in
the 4 weeks before baseline, %*
48.57 55.95
*Significant at p < 0.05 Abbreviations: BMI body mass index, ADHD attention-deficit/
hyperactivity disorder, CGI-ADHD-S Clinical Global Impressions-ADHD-Severity, CSI-4
Child Symptom Inventory-4 Parent Checklist, SD standard deviation.
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[SD 1.01]; CSI-4, 80.14 [SD 10.27]) and lowest in those who
initiated other treatments or no treatments/interventions.
Mean age was also highest in the combination group (9.32
[SD 2.54]) but lowest in the psychotherapy only group (8.34
[SD 1.95]).
The baseline patient characteristics by treatment initi-
ation (i.e., psychotherapy and/or pharmacotherapy) are
reported in Table 2. Patients who initiated treatment at
baseline were more likely to be living in Central Europe,
have had birth problems, have had primary care visits for
behavioural problems in the 4 weeks before baseline, been
truant in the 4 weeks before baseline, have parents/guard-
ians experiencing emotional difficulties due to their child’s
behavioural problems, have mothers not in paid employ-
ment, and have been invited to social activities in the
4 weeks before baseline. In addition, these patients were
older and had greater mean clinical severity (i.e., higher
CGI-ADHD-S and CSI-4 scores).
Patient characteristics associated with treatment initiation
at baseline
Table 3 shows the results of logistic regression, which
examined patients’ baseline characteristics associated
with treatment initiation. At baseline, patients who initi-
ated treatment tended to be older, have had birth prob-
lems, and have higher CGI-ADHD-S and CSI-4 scores,
whereas those who did not initiate treatment tended to
have been involved in bullying (as a bully) and have a
working mother.
In East Asia, being older (odds ratio [OR] = 1.17; 95%
confidence interval [CI], 1.04, 1.31; p = 0.009), being male
(OR = 1.95; 95% CI 1.02, 3.73; p = 0.043), and havinghigher CGI-ADHD-S scores (OR = 1.61; 95% CI 1.19, 2.17;
p = 0.002) were associated with treatment initiation. In
Central Europe, parental psychological distress (OR = 4.33;
95% CI 1.91, 9.81; p < 0.001) and having higher CSI-4
scores (OR = 1.04; 95% CI 1.01, 1.07; p = 0.022) were posi-
tively associated with treatment initiation, whereas being
involved in bullying (as a bully) (OR = 0.27; 95% CI 0.13,
0.60; p = 0.001) was inversely associated with treatment
initiation at baseline. Notably, of these variables, being
male and parental psychological distress exhibited dif-
ferent directions of odds ratios for treatment initiation
in these regional subgroup analyses, and their interac-
tions with region appeared to be statistically significant
(0.034 for being male and <0.001 for parental psycho-
logical distress).
Discussion
There is now high-quality evidence supporting the effi-
cacy and effectiveness of a range of pharmacological
treatments in the management of children and adoles-
cents with ADHD [8,10]. In addition, a number of
Table 3 Factors associated with treatment initiation at baseline
All East Asia only Central Europe only Interaction
with region‡
Baseline factors OR† 95% CI P-value OR† 95% CI P-value OR† 95% CI P-value P-value
Age 1.14 1.04, 1.24 0.005* 1.17 1.04, 1.31 0.009* 1.04 0.89, 1.21 0.599 0.227
Age at first symptoms 1.00 0.91, 1.10 0.995 0.97 0.85, 1.10 0.633 1.02 0.87, 1.19 0.835 0.622
Being male 1.24 0.74, 2.07 0.421 1.95 1.02, 3.73 0.043* 0.46 0.16, 1.33 0.154 0.034*
Being from East Asia 0.87 0.56, 1.36 0.533 - - - - - - -
Having birth problems 1.86 1.14, 3.02 0.013* 1.76 0.90, 3.45 0.099 1.74 0.79, 3.80 0.167 0.662
Family history of ADHD 1.08 0.71, 1.63 0.730 1.23 0.71, 2.14 0.463 0.94 0.47, 1.88 0.856 0.948
Higher CGI-ADHD-S scores 1.32 1.07, 1.63 0.010* 1.61 1.19, 2.17 0.002* 1.02 0.73, 1.43 0.915 0.185
Higher CSI-4 scores 1.03 1.01, 1.05 0.013* 1.02 0.99, 1.05 0.189 1.04 1.01, 1.07 0.022* 0.877
Having a working mother 0.60 0.38, 0.94 0.026* 0.68 0.38, 1.22 0.199 0.47 0.21, 1.05 0.066 0.291
Parental psychological distress 1.20 0.80, 1.81 0.376 0.64 0.38, 1.09 0.103 4.33 1.91, 9.81 <0.001* <0.001*
Being truant§ 1.47 0.56, 3.82 0.434 2.22 0.44, 11.14 0.334 1.83 0.49, 6.77 0.368 0.428
Being involved in bullying (as a bully)§ 0.55 0.36, 0.85 0.007* 0.82 0.47, 1.44 0.491 0.27 0.13, 0.60 0.001* 0.674
Primary care visit for behavioural problems§ 1.69 0.86, 3.34 0.130 1.90 0.81, 4.49 0.141 1.28 0.36, 4.61 0.702 0.912
Being invited to social activity§ 1.23 0.83, 1.82 0.309 1.39 0.83, 2.33 0.216 1.27 0.64, 2.52 0.496 0.019*
†OR > 1 indicates a positive association with treatment initiation. The models included patient age, gender, age at first symptoms, region, birth problems, a family
history of ADHD, and CGI-ADHD-S score. The rest of the variables were also included as they appeared to be significant at p < 0.1 in simple regressions with the
whole sample. The same list of the variables were also included in the subgroup analyses by region, except for the variable “region”.
‡These p-values are for the interactions between region and each specific variable taken from the models that included region, each specific variable, and their
“interaction” term.
§Behaviour in the 4 weeks before baseline.
*The asterisks (*) indicate p-values of <0.05.
Abbreviations: ADHD attention-deficit/hyperactivity disorder, CGI-ADHD-S Clinical Global Impressions-ADHD-Severity, CSI-4 Child Symptom Inventory-4 Parent
Checklist, OR odds ratio, CI confidence interval.
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ment options for ADHD, although their effects have
been challenged by a recent meta-analysis limited to tri-
als with “probably blind” assessment [26]. The findings
of this large 1-year observational study, however, re-
vealed that 25.7% of patients newly diagnosed with
ADHD symptoms in Central Europe and East Asia did
not initiate treatment (i.e., pharmacotherapy and/or psy-
chotherapy) at baseline. This rate was higher in East
Asia (30.1%) compared with Central Europe (21.7%),
mainly due to a higher rate of other nonconventional
treatments (e.g., herbal therapy) prescribed in East Asia.
Nevertheless, clinical severity appeared to be one of the
most important determinants of treatment initiation in
both regions.
The role of clinical severity in treatment decision mak-
ing may be even greater in East Asia than Central Europe.
There were only three factors associated with treatment
initiation in East Asia, which were being older, being male,
and having higher clinical severity (measured by the CGI-
ADHD-S). These three factors may indicate more severe
clinical symptoms and a higher tolerability of drug treat-
ments. Given the high acceptance of herbal treatments
(traditional Chinese medicine) and high levels of stigma
attached to mental illness in East Asia [15], it is possible
that the initiation of formal treatment for ADHD is moreconservative in this region, thereby its use is strictly lim-
ited to school-aged children and adolescents with severe
clinical symptoms and impairments, as hypothesised.
However, it is noteworthy that the role of clinical se-
verity or patient age does not appear to be obvious when
making the decision between pharmacotherapy and psy-
chotherapy in actual clinical practice in East Asia. Level
of clinical severity was highest in a subgroup of patients
who initiated psychotherapy only. This is somewhat in-
consistent with international guidelines, which generally
recommend the use of psychotherapy for milder ADHD
and for younger children [8,10,11]. This might be partly
due to the composition of our patient sample, who were
patients newly diagnosed with ADHD symptoms, al-
though the same pattern was not observed in Central
Europe. Alternatively, this could reflect negative atti-
tudes toward the use of medications for ADHD in East
Asia, which might be much stronger there than in other
parts of the world [27].
Clinical severity was also associated with treatment initi-
ation at the baseline visit in Central Europe. Although it
was highest in the subgroup of patients who initiated both
psychotherapy and pharmacotherapy, 48.8% of patients
started with the combination treatment at baseline,
despite the fact that patients were all “newly” diag-
nosed with ADHD; this rate is much higher than that
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crepancy in treatment practices that needs to be fur-
ther investigated.
In addition to clinical severity, parental psychological
distress due to their child’s behavioural problems was
also strongly associated with treatment initiation in this
region. Although this variable could, in part, reflect the
level of clinical severity of their affected child, it is not
clear why this relationship was not observed in East
Asia. In fact, parental psychological distress was in-
versely associated with treatment initiation in East Asia,
although the association was not statistically significant
(OR = 0.64; 95% CI 0.38 – 1.09; p = 0.103). The inter-
action between region and parental psychological
distress, however, still appeared to be statistically sig-
nificant (p < 0.001). Interestingly, previous research
using the same data found that parental psychological
distress was associated with medication nonadherence
during follow-up in East Asia but not in Central
Europe [20]. The Taiwanese study by Gau et al. also re-
ported similar findings [28].
These seemingly contradictory findings may imply
that different mechanisms underlie the impacts and
causes of parental psychological distress in these re-
gions. In Central Europe, parental psychological distress
may indicate a greater need for professional help on
their affected child and could be one of the main deter-
minants of the decision to seek help, whereas in East
Asia, the impacts and causes of parental psychological
distress could be more complex. Many parents of chil-
dren and adolescents with ADHD in East Asia tend to
take personal responsibility for their child’s behavioural
problems and often have negative attitudes toward the
use of medications for ADHD [27]. In East Asia, parents
who also take heavy responsibility for their child’s prob-
lems and extensively intervene to mediate behaviour are
also more likely to be those who have psychological dis-
tress caused by their child’s behavioural problems. It is
possible that these types of parents are more conserva-
tive in the use of medication for their child’s ADHD
symptoms and are willing to initiate treatments only
when their child’s symptoms are sufficiently severe and
cannot be appropriately controlled by their own inter-
ventions. They may also stop such treatments more eas-
ily once their child’s symptoms improve, potentially
leading to a higher level of medication nonadherence in
East Asia. Further research, culturally sensitive, is re-
quired to better understand the role of parental psycho-
logical distress in the treatment of ADHD.
Our study also found an inverse association between
being involved in bullying (as a bully) and treatment
initiation at baseline in Central Europe. It should be
noted that a similar association was also observed in
East Asia, but it was not statistically significant (OR =0.82; 95% CI 0.47-1.44; p = 0.491). Although the reason
for this inverse association is not clear, it is possible
that given a higher possibility of other comorbid condi-
tions among these patients (e.g., conduct disorder),
clinicians could have needed more time to observe
their symptoms before making a correct diagnosis and
subsequent treatment plans. In addition, the use of
stimulants, which were the only medications (or dom-
inant medications) available for the treatment of
ADHD in many countries in Central Europe and East
Asia at the time this observational study was con-
ducted, might have been discouraged for these chil-
dren as first-line therapy due to potential risks of drug
abuse or diversion.
However, several limitations of this study should be
taken into account when interpreting these results.
Firstly, given its observational design, the associations
found in our study do not imply causal relationships.
Secondly, the patients included in our study were diag-
nosed with the symptoms of ADHD, not necessarily with
ADHD itself. The broader inclusion criteria were de-
signed to observe and describe the similarities and dif-
ferences in actual treatment practices and prescription
patterns across several countries in Central Europe and
East Asia. Although this is not a limitation in the con-
text of our study, the role of clinical severity in treat-
ment decision making could have been greater with
such patients because they are potentially more hetero-
geneous in terms of symptom severity. Thirdly, the
treatment initiation can also be influenced by the socio-
economic status of patients (e.g., income, insurance),
especially in Central Europe and East Asia, where a high
level of patient cost-sharing is common. However, due
to data constraints, our study was unable to assess their
impact on treatment initiation. Finally, although this
observational study included more than one thousand
patients, they may not be representative of the paediat-
ric patients with ADHD symptoms in Central Europe
and East Asia.Conclusions
Our findings indicate systematic differences in patient
characteristics between patients who did and did not
initiate treatment (pharmacotherapy and/or psychother-
apy) at baseline in the treatment of ADHD symptoms.
Although factors associated with treatment initiation
differed to some extent between Central Europe and
East Asia, clinical severity appeared to be one of the
most important determinants of treatment initiation in
both regions but was possibly more so in East Asia.
However, the choice between pharmacotherapy and
psychotherapy, either alone or in combination, varied
substantially across the regions.
Hong et al. BMC Psychiatry 2014, 14:304 Page 8 of 8
http://www.biomedcentral.com/1471-244X/14/304Additional file
Additional file 1: A list of all ethical review boards that approved
the B4Z-VI-B004 observational study.
Competing interests
Jihyung Hong is a consultant for Eli Lilly and Company. Diego Novick, Tamás
Treuer, Virginia S. Haynes, and Shenghu Wu are employees of Eli Lilly and
Company Limited. Josep Maria Haro has acted as a consultant, received grants,
or acted as a speaker in activities sponsored by the following companies:
Astra-Zeneca, Eli Lilly and Company, Glaxo-Smith-Kline, and Lundbeck.
Authors’ contributions
JH conducted the statistical analysis and drafted the manuscript. DN, TT, WM,
VSH, SW and JMH participated in the design of the present study and
provided critical review of the manuscript. All authors have read and
approved the final manuscript.
Acknowledgments
The study was sponsored by Eli Lilly and Company.
Author details
1Eli Lilly and Company, Windlesham, Surrey, UK. 2Eli Lilly and Company,
Neuroscience Research, Budapest, Hungary. 3Eli Lilly Australia Pty Ltd, West
Ryde, Australia. 4Eli Lilly and Company, Indianapolis, IN, USA. 5Eli Lilly China,
Shanghai, China. 6Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de
Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain.
Received: 28 January 2014 Accepted: 16 October 2014
References
1. Biederman J, Faraone SV: Attention-deficit hyperactivity disorder.
Lancet 2005, 366(9481):237–248.
2. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA: ADHD
prevalence estimates across three decades: an updated systematic
review and meta-regression analysis. Int J Epidemiol 2014, 43(2):434–442.
3. Chae PK, Jung HO, Noh KS: Attention deficit hyperactivty disorder in
Korean juvenile delinquents. Adolescence 2001, 36(144):707–725.
4. Ersan EE, Dogan O, Dogan S, Sumer H: The distribution of symptoms of
attention-deficit/hyperactivity disorder and oppositional defiant disorder
in school age children in Turkey. Eur Child Adolesc Psychiatry 2004,
13(6):354–361.
5. Gau SS, Chong MY, Chen TH, Cheng AT: A 3-year panel study of mental
disorders among adolescents in Taiwan. Am J Psychiatry 2005,
162(7):1344–1350.
6. Takahashi K, Miyawaki D, Suzuki F, Mamoto A, Matsushima N, Tsuji H, Horino A,
Ballas PA, Kiriike N: Hyperactivity and comorbidity in Japanese children with
attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci 2007,
61(3):255–262.
7. Hirfanoglu T, Soysal AS, Gucuyener K, Cansu A, Serdaroglu A: A study of
perceptions, attitudes, and level of knowledge among pediatricians
towards attention-deficit/hyperactivity disorder. Turk J Pediatr 2008,
50(2):160–166.
8. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J,
Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC,
Zuddas A: European clinical guidelines for hyperkinetic disorder – first
upgrade. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I7–I30.
9. Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K,
Wolraich ML: Treatment of attention-deficit/hyperactivity disorder: overview
of the evidence. Pediatrics 2005, 115(6):e749–e757.
10. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee
on Quality Improvement and Management, Wolraich M, Brown L, Brown RT,
DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J,
Pierce K, Reiff M, Stein MT, Visser S: ADHD: clinical practice guideline for the
diagnosis, evaluation, and treatment of attention-deficit/hyperactivity
disorder in children and adolescents. Pediatrics 2011, 128(5):1007–1022.
11. National Institute for Health and Care Excellence: Attention deficit
hyperactivity disorder. Diagnosis and management of ADHD in children, young
people and adults. NICE clinical guideline 72. London: NICE; 2008.12. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts
M, Dittmann RW, Graham J, Taylor E, Sergeant J, on behalf of the European
ADHD Guidelines Group: Practitioner Review: Current best practice in the
management of adverse events during treatment with ADHD
medications in children and adolescents. J Child Psychol Psychiatry 2013,
54(3):227–246.
13. Falissard B, Coghill D, Rothenberger A, Lorenzo M: Short-term effectiveness
of medication and psychosocial intervention in a cohort of newly
diagnosed patients with inattention, impulsivity, and hyperactivity
problems. J Atten Disord 2010, 14(2):147–156.
14. Chen CY, Gerhard T, Winterstein AG: Determinants of initial pharmacological
treatment for youths with attention-deficit/hyperactivity disorder. J Child
Adolesc Psychopharmacol 2009, 19(2):187–195.
15. Hinshaw SP, Scheffler RM, Fulton BD, Aase H, Banaschewski T, Cheng W,
Mattos P, Holte A, Levy F, Sadeh A, Sergeant JA, Taylor E, Weiss MD:
International variation in treatment procedures for ADHD: social context
and recent trends. Psychiatr Serv 2011, 62(5):459–464.
16. Martenyi F, Treuer T, Gau SS, Hong SD, Palaczky M, Suba J, Tiberiu M,
Uhlikova P, Xu T, Zoroglu S, Gadow KD, Walton R, Harrison G: Attention-
deficit/hyperactivity disorder diagnosis, co-morbidities, treatment
patterns, and quality of life in a pediatric population in central and eastern
Europe and Asia. J Child Adolesc Psychopharmacol 2009, 19(4):363–376.
17. Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO,
Bardenstein LM, Kozlova IA, Neznanov NG, Maslova OI, Petrukhin AS,
Sukchotina NK, Zykov VP: Atomoxetine in children and adolescents with
attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-
controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry 2010,
19(1):57–66.
18. Martenyi F, Zheng Y, Huang YS, Lee YS, Walton R, Harrison G, Treuer T:
A prospective observational study of attention-deficit hyperactivity
disorder in Asia: baseline characteristics of symptom severity and
treatment options in a paediatric population. East Asian Archives Psychiatry
2010, 20(2):76–86.
19. Goetz M, Yeh C-B, Ondrejka I, Akay A, Herczeg I, Dobrescu I, Kim BN, Jin X,
Riley AW, Martenyi F, Harrison G, Treuer T: A 12-month prospective,
observational study of treatment regimen and quality of life associated
with ADHD in central and eastern europe and eastern Asia. J Atten Disord
2012, 16(1):44–59.
20. Hong J, Novick D, Treuer T, Montgomery W, Haynes VS, Wu S, Haro JM:
Predictors and consequences of adherence to the treatment of pediatric
patients with attention-deficit/hyperactivity disorder in Central Europe
and East Asia. Patient Preference Adherence 2013, 7:987–995.
21. APA: Diagnostic and statistical manual of mental disorders (4th edition; text
revision). Washington, DC: American Psychiatric Association (APA); 2000.
22. World Health Organization: The ICD-10 Classification of Mental and Behavioural
Disorders. Clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.
23. Guy W: ECDEU assessment manual for psychopharmacology (Revised).
Bethesda, MD: U.S. Department of Health, Education and Welfare; 1976.
24. Gadow KD, Sprafkin J: Childhood Symptom Inventory 4. Screening and Norms
Manual. Stony Brook, NY: Checkmate Plus; 2002.
25. SAS Institute Inc.: SAS 9.1 Software. Cary, North Carolina: SAS Institute Inc.
26. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M,
Stevenson J, Danckaerts M, van der Oord S, Dopfner M, Dittmann RW,
Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C,
Konofal E, Lecendreux M, Wong IC, Sergeant J: Nonpharmacological
interventions for ADHD: systematic review and meta-analyses of
randomized controlled trials of dietary and psychological treatments.
Am J Psychiatry 2013, 170(3):275–289.
27. Moon SY: Cultural perspectives on attention deficit hyperactivity
disorder: A comparison between Korea and the U.S. J Int Bus Cult Stud
2011, 6:1.
28. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS: Determinants of
adherence to methylphenidate and the impact of poor adherence on
maternal and family measures. J Child Adolesc Psychopharmacol 2006,
16(3):286–297.
doi:10.1186/s12888-014-0304-x
Cite this article as: Hong et al.: Patient characteristics associated with
treatment initiation among paediatric patients with Attention-Deficit/
Hyperactivity Disorder symptoms in a naturalistic setting in
Central Europe and East Asia. BMC Psychiatry 2014 14:304.
